Reaching cellular immunotherapy milestones faster: real-world insights
Join a panel of industry leaders as they share hard-won insights and practical strategies for advancing cellular immunotherapies through the complexities of clinical and commercial translation.
Streamline your process development
Gain a clear roadmap to scale up cell therapy processes while maintaining regulatory compliance, plus proven methodologies in cell manufacturing and analytical testing that support scalability and regulatory compliance. Learn strategic approaches to improve collaboration across CMC, MSAT, process development and analytical functions.
Learn from real-world experience
Hear first-hand experiences from experts who have successfully tackled scalability, compliance, and cross-functional collaboration challenges. Their candid reflections on what’s worked – and what hasn’t – offer valuable lessons you can apply directly to your own context.
Join the webinar for:
- Practical guidance on streamlining process development and scale-up
- Insights into emerging trends shaping CGT clinical and commercial success
- Real-world examples of effective methodologies in cell manufacturing and analytical testing that can be adapted to your own roadmap
Boris Engels
Senior Scientific Director for Gene-Engineered T Cell Therapies at Miltenyi Biotec
Boris Engels, Ph.D., is Senior Scientific Director for Gene-Engineered T Cell Therapies at Miltenyi Biotec, leading multidisciplinary teams developing CAR- and TCR-redirected T cells for cancer and autoimmune disease. His work spans target discovery, next-generation CAR design, and early clinical development. Previously, he built the cell therapy group at Novartis Institutes for Biomedical Research, conducted postdoctoral research at the University of Chicago, and earned his Ph.D. at the Max-Delbrück Centre/Freie Universität Berlin.
Marsilius Mues
R&D Group Leader - Assay Development Cellular Immunotherapy at Miltenyi Biotec
Dr. Mues joined the R&D Department of Miltenyi Biotec in 2017. In his current role he leads the interdisciplinary research and development in the field of immuno-oncology and cellular therapeutics, with a focus on CAR T cell engineering for personalized immunotherapy. He oversees the establishment of multiparametric immune assays for functional characterization of engineered T cells, along with automated data acquisition and analysis tools for translational research, cell therapy manufacturing, and patient immune monitoring during clinical trials. He performed his PhD studies at the Max Planck Institute of Neurobiology on T cell signaling during autoimmune disease and completed his postdoctoral research at UCSF where he focused on novel combinatorial therapies using high-complexity lentiviral shRNA & CRISPR/Cas9 libraries for T-cell leukemia.
Arindam Mitra
Director, CMC at Leucid Bio
Arindam Mitra is an biotechnology professional with over 13 years of experience in lean manufacturing strategies including CMC regulatory strategies focused on early market access. Further, he has professional experience encompassing manufacture process development, analytical process development, and routine manufacture for clinical delivery for first-in-human trials of cell and gene therapy products. He has developed campaign manufacture strategies and cost-effective manufacture models and has an interest in developing sustainable carbon neutral processes. He has worked in Europe’s first double-blinded cell therapy study and developed over 13 cell and gene therapies from pre-clinical concepts, including cell therapeutics for long COVID patients featured on the BBC. He has held several leadership positions in organizations such as Cell Medica Ltd and King’s College London Guy’s Hospital BRC, and currently serves as the Director, CMC Operations at Leucid Bio, London, UK.
Masoud Golshadi
Senior Scientist at Takeda
Masoud is a Senior Scientist at Takeda with extensive experience in cell therapy, specializing in both CMC and translational/clinical environments. As a subject matter expert in flow cytometry and immunophenotyping, he has led the development and optimization of critical release assays for CAR-NK, γδT, and neoantigen-based cell therapy programs. With a strong background in immunological-based assay development and a proven track record of successful project management and tech-transfer, he is a results-driven professional with deep knowledge of QA/FDA compliance and a commitment to advancing cancer immunotherapies
